

## **Developmental trajectories in infants and pre-school children with Neurofibromatosis 1**

Hannah Slevin<sup>1\*</sup>, MRCPsych, Fiona Kehinde<sup>1\*</sup>, MB BChir MA (Cantab), Jannath Begum-Ali<sup>2</sup>, PhD, Ceri Ellis<sup>1</sup>, PhD, Emma Burkitt-Wright<sup>3,4</sup>, MbChB, PhD, Jonathan Green<sup>1,5</sup>, FRCPsych, Mark H. Johnson<sup>2,6</sup>, PhD, Greg Pasco<sup>7</sup>, PhD, Tony Charman<sup>7</sup>, PhD, Emily J.H Jones<sup>2</sup>, PhD, and Shruti Garg<sup>1,5</sup>, PhD on behalf of the EDEN-STAARS team\*\*.

\*Contributed equally as first authors

\*\* A complete list of study group members appears in the Acknowledgments

**Affiliations** <sup>1</sup>Division of Psychology, Communication and Human Neuroscience, School of Health Sciences, University of Manchester, Manchester, United Kingdom,

<sup>2</sup>Centre for Brain and Cognitive Development and Department of Psychological Sciences, Birkbeck, University of London, London, United Kingdom,

<sup>3</sup>Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

<sup>4</sup>Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom,

<sup>5</sup>Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom,

<sup>6</sup>Department of Psychology, University of Cambridge, Cambridge, United Kingdom,

<sup>7</sup>Psychology Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

**Address correspondence to:** Dr Shruti Garg [shruti.garg@manchester.ac.uk](mailto:shruti.garg@manchester.ac.uk)

**Short title:** Developmental trajectories in NF1 infants and children

**Conflict of Interest Disclosures (includes financial disclosures):** TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier; and has received royalties from Sage Publications and Guilford Publications. The other authors have no conflicts of interest to disclose.

**Funding/Support:** This study was supported by Action for Medical Research (GN2385), Rosetrees Trust (A2213), Medical Research Council (MR/K021389/1; MR/T003057/1) and MQ (MQ14PP\_83). This study was also supported by the EU-AIMS and AIMS-2-TRIALS programmes funded by the Innovative Medicines Initiative Joint Undertaking Grant No.115300 and No. 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme, with contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and funding from Autism Speaks, Autistica and SFARI. This work was also supported by Action for Medical Research, Great Ormond Street Hospital Children's Charity and the Bailey Thomas Charitable Fund (GN2385), Rosetrees Trust (A2213). Shruti Garg is a Francis Collins Scholar supported by Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the John Hopkins University. Jonathan Green is supported by NIHR Senior Investigator Award. Hannah Slevin is an NIHR Academic Clinical Fellow and Fiona Kehinde is a Houghton-Dunn research associate.

**Role of Funder/Sponsor (if any) disclaimer:** The funders had no role in the design of the

study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders.

**Clinical Trial Registration (if any):** The studies involving human participants were approved by Greater Manchester Central Research Ethics committee (16/NW/0324) and National Research Ethics Service London Central Ethical Committee (16/EE/0167 and 06/MRE02/73). Written informed consent for study participation was obtained from the participant's legal guardian/next of kin.

**Data sharing statement:** Deidentified participant data is available through the STAARS network via data sharing procedures that comply with ethical requirements, due to the sensitive nature of the data collected. Available at: <https://www.basisnetwork.org/>. There is no known end date of data availability.

**Abbreviations:** NF1: neurofibromatosis type 1; ADHD: attention deficit hyperactivity disorder; MSEL: Mullen Scales of Early Learning; VABS: Vineland Adaptive Behavior Scales; ADOS-2: Autism Diagnostic Observation Schedule; BOSA-MV: Brief Observation of Symptoms of Autism for Minimally Verbal children; ADI-R: Autism Diagnostic Interview-Revised; CBCL: Child Behavior Checklist.

### **Article Summary**

This prospective study examines cognitive and adaptive functioning, ADHD and autism traits in children with Neurofibromatosis 1 aged 5-36 months versus typically developing children.

### **What's Known on This Subject**

Pre-school children with NF1 demonstrate cognitive, behavioural and social differences compared to peers. Evidence suggests that children with NF1 have higher rates of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder. However, the age at which differences emerge remains unclear.

### **What This Study Adds**

This study examined trajectories from infancy of children with NF1 to detect the earliest age of onset of cognitive and behavioural differences. Differences between NF1 and TD infants emerged from 24 months of age.

### **Contributors Statement Page**

Dr Hannah Slevin and Dr Fiona Kehinde led the analysis, interpreted the results, drafted the manuscript and commented on the revisions.

Dr Jannath Begum-Ali led the fieldwork assessments, led data entry and initial analysis, led the quality control of phenotypic data and contributed to the critical review of the manuscript.

Dr Ceri Ellis contributed to the fieldwork assessments, led data entry, led the quality control of phenotypic data and contributed to the critical review of the manuscript.

Dr Emma Burkitt-Wright identified and recruited participants and contributed to the critical review of the manuscript.

Professor Jonathan Green conceptualised the study and design, gained funding, critically reviewed and revised the manuscript.

Professor Mark H. Johnson conceptualised and designed the study, gained funding and critically reviewed and revised the manuscript.

Dr Greg Pasco contributed to data collection and critically reviewed the manuscript.

Professor Tony Charman conceptualised and designed the study, supervised the field-work and critically reviewed the manuscript.

Professor Emily Jones conceptualised the study design, gained funding, , supervised the field-work and critically reviewed and revised the manuscript.

Dr Shruti Garg conceptualised the study design, gained funding, led the recruitment, supervised the fieldwork and analyses, contributed to interpretation of findings and critically reviewed and revised the manuscript.

The EDEN-STAARS team recruited participants and conducted all fieldwork assessments.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

## Abstract

**Objective:** This prospective cohort study examines the cognitive, behavioural, ADHD trait and autism symptom development in infant and pre-school children with Neurofibromatosis 1 (NF1) compared with typically developing (TD) children without a family history of neurodevelopmental conditions.

**Methods:** Data from standardised tests was gathered at 5, 10, 14, 24 and 36 months of age (NF1 n=35, TD n=29). Developmental trajectories of cognitive and adaptive behavioural development from 5 to 36 months were analysed using linear mixed modelling. Measures of ADHD and autism traits were assessed at 24 and 36 months.

**Results:** The developmental trajectory of cognitive skills (all domains of the Mullen Scales of Early Learning -MSEL) and behavioural skills (four domains of the Vineland Adaptive Behaviour Scale -VABS) differed significantly between NF1 and TD groups. Post-hoc tests demonstrated that the NF1 participants scored significantly lower than TD participants at 24 months on all MSEL and VABS domains. The NF1 cohort demonstrated higher mean autism and ADHD traits at 24 months and 14% of the NF1 cohort met a research diagnostic classification for autism at 36 months.

**Conclusion:** By 24 months of age, the NF1 cohort show lower cognitive skills and adaptive behaviour and higher levels of autism and ADHD traits as compared to TD children.

## 1 INTRODUCTION

2 Neurofibromatosis 1 (NF1) is a single gene neurocutaneous condition, with a birth incidence  
3 of 1 in 2700.<sup>1</sup> 50% of cases arise through autosomal dominant inheritance from a parent, and  
4 50% via a sporadic pathogenic variant of the tumour-suppressor NF1 gene on chromosome  
5 17q11.2. This gene codes for the protein neurofibromin, which plays a role in regulating  
6 neuronal cell development.<sup>2</sup> NF1 is characterised by phenotypic variability, and clinical  
7 diagnosis is based on the revised National Institute of Health (NIH) criteria.<sup>3</sup>

8 Many children with NF1 experience cognitive and behavioural difficulties which impact their  
9 quality of life. Overall intellectual ability is only slightly lower than children who do not have  
10 NF1, however specific cognitive deficits impact perceptual (particularly visuospatial) skills,  
11 executive functioning, adaptive behaviour, attention and motor skills.<sup>4,5</sup> Research also  
12 indicates high rates of co-occurring conditions such as Autism Spectrum Disorder  
13 (henceforth referred to as autism) (29%) and Attention Deficit Hyperactivity Disorder  
14 (ADHD) (50%).<sup>6,7</sup>

15 The majority of studies analysing the cognitive, social and behavioural phenotype in NF1  
16 have concentrated on school-aged children. Several cross-sectional studies have focused on  
17 the pre-school period, which consistently demonstrate that young children with NF1 show  
18 cognitive, behavioural and social differences compared to age-matched controls.<sup>2,4,8-12</sup>  
19 However, the age and sequence at which these differences begin to emerge is not fully  
20 understood. Understanding this is crucial for identifying early markers of later  
21 neurodevelopmental outcomes, and has clinical implications for screening and intervention,  
22 particularly educational planning.<sup>13</sup>

23 Two previous studies have analysed trajectories of cognitive development in toddlers.<sup>14,15</sup>  
24 Lorenzo et al (2015) assessed the early development of 39 children with NF1 aged 21, 30 and

25 40 months compared with matched controls; the NF1 cohort demonstrated lower cognitive  
26 functioning than controls.<sup>14</sup> Wessel et al (2013) assessed 124 infants with NF1 at a range of  
27 ages (0-8) using parental report measures. Gross and fine motor delays were found to emerge  
28 aged 3-5, whereas academic delays tended to present at a later age.<sup>15</sup> However, the majority  
29 of the cohort had just one assessment.

30 Previous papers from our group examined trajectories of cognitive and adaptive behavioural  
31 development in infants with NF1 aged 5 to 14 months compared with typically developing  
32 (TD) children.<sup>13</sup> At this early stage in development, no group differences were observed in  
33 trajectories of cognitive and adaptive functioning, nor differences on social communication  
34 measures. However, early differences in neural processing including auditory processing and  
35 excitation/inhibition balance were observed, both of which were related to later autistic  
36 traits.<sup>16,17</sup>

37 Our study aim is to examine the early cognitive, behavioural, autism and ADHD trait  
38 development of infants and pre-school aged children with NF1, compared with a cohort of  
39 TD children. Our objectives were to build on the earlier work of our team<sup>13</sup> by examining  
40 longitudinal trajectories of cognitive and behavioural development from 5-36 months, and  
41 ADHD trait development at 24 and 36 months. We also aimed to examine emergence of  
42 autism traits at 24 and 36 months.

43 We hypothesised that children with NF1 would have lower cognitive and adaptive  
44 functioning over time, and higher levels of ADHD and autism traits compared with TD  
45 children. Based on our previous work, we interrogate whether differences begin to emerge at  
46 age 24 or 36 months. To our knowledge, this is the first study to examine cognitive and  
47 behavioural development from infancy in children with NF1 using both parental report and  
48 objective assessment measures. This prospective approach is critical in avoiding

49 ascertainment bias seen with older children, where participants may be more likely to  
50 participate if they are experiencing developmental delays.

## 51 **METHODS**

52 The Early Development in NF1 (EDEN) study is a UK-based prospective longitudinal cohort  
53 study investigating early development in infants and children with NF1. Participants were  
54 enrolled through regional genetic centres and NF1 charities. Participants in the TD group  
55 were recruited from the Studying Autism and ADHD in at Risk Siblings (STAARS) study at  
56 the Centre for Brain and Cognitive Development, Birkbeck, University of London.  
57 Participants were assessed at 5, 10, 14, 24 and 36 months of age. Rolling recruitment was  
58 conducted between 2016-2019.

59 Inclusion criteria for the NF1 cohort included a) infants up to 16 months of age at the time of  
60 recruitment b) NF1 diagnosed via testing of cord blood samples or clinical diagnosis.

61 Inclusion criteria for the TD group included a) infants up to 16 months of age at the time of  
62 recruitment b) no first-degree relatives with known genetic conditions, autism or Attention  
63 Deficit Hyperactivity Disorder (ADHD) c) no parent-reported developmental issues d) full-  
64 term birth (gestational age at least 36 weeks).

65 Exclusion criteria for both groups included a) conditions which might make it difficult for the  
66 infant to participate, including serious physical complications of NF1 b) significant hearing  
67 or visual impairments c) significant prematurity d) parents with significant learning  
68 difficulties or who were unable to give informed consent.

69 Procedural details are included in **Supplementary materials**.

## 70 **Measures**

71 *Maternal education*

72 Maternal education was classified as either primary, secondary, undergraduate or  
73 postgraduate (1,2,3 or 4) (**Table 1**). This has been shown to be significantly associated with  
74 trajectories of cognitive and adaptive functioning at 5, 10 and 14 months in this population.<sup>15</sup>

75 *Cognitive and adaptive behavioural skills*

76 The Mullen Scales of Early Learning (MSEL),<sup>18</sup> a standardised assessment for children aged  
77 up to 68 months, was used to assess cognitive functioning at all five time points. Five  
78 domains were assessed, including Visual Reception, Fine Motor, Receptive Language,  
79 Expressive Language skills (all measured as T-scores) and an Early Learning Composite  
80 (ELC) (Standard Score).

81 The Vineland Adaptive Behavior Scale (VABS),<sup>19</sup> a parent-report questionnaire, was used to  
82 assess adaptive behavioural skills at all five time points. Five domains were assessed,  
83 including Communication, Daily Living Skills, Socialisation, Motor skills and an Adaptive  
84 Behaviour Composite score. Analyses used Standard Scores.

85 *ADHD traits*

86 The Child Behaviour Checklist (CBCL) for ages 1.5-5,<sup>20</sup> a parent-report questionnaire, was  
87 used to assess ADHD traits (inattention/hyperactivity) at 24 and 36 month time points. T-  
88 scores were used for the DSM-orientated Attention Deficit Hyperactivity problems scale. T-  
89 scores of 70 are in the clinically significant range, and 65-69 considered borderline.

90 *Autism traits*

91 The Autism Diagnostic Observation Schedule (ADOS-2), a semi-structured assessment of  
92 social communication, social interaction and imaginative play for individuals suspected to



93 have autism,<sup>21,22</sup> was utilised at 24 and 36 months. Due to social distancing constraints  
94 necessitated by the Covid-19 pandemic, some assessments instead utilised the Brief  
95 Observation of Symptoms of Autism for Minimally Verbal children (BOSA-MV), an  
96 observational measure designed to be administered remotely.<sup>23</sup> **Table 3** outlines the  
97 participant numbers at each timepoint who were administered ADOS-2 versus BOSA.  
98 The Autism Diagnostic Interview-Revised (ADI-R), an investigator-based semi-structured  
99 interview for parents,<sup>24</sup> was carried out at 36 months.

100 The **Supplementary Materials** outline diagnostic thresholds on the ADOS-2, BOSA and  
101 ADI-R, and detail how a research classification of autism was determined at 36 months.

## 102 **Statistical analyses**

103 Statistical analyses were performed using IBM SPSS Statistics 28.0.0.0. Linear mixed  
104 modelling was used to analyse the change in cognition (MSEL), adaptive behaviour (VABS)  
105 and ADHD traits (CBCL DSM-ADHD subscale) over time. For each subscale, overall group  
106 differences were modelled using fixed effects (group, timepoint and sex) and random effects  
107 (ID - individual variation). Maternal education was included as a co-variate within the  
108 model.<sup>15</sup> Maternal education significantly differed between groups, with mothers of TD  
109 children more likely to have a post-graduate education (Median NF1: 2, TD: 4  $X^2(2) = 19.79$ ,  
110  $p < 0.001$ ).

111 In all models, sex was non-significant (**Table 2**). The NF1 group was significantly older than  
112 the TD group at 5 months ( $t = 3.09$ , 95% CI 5.36 to 25.72 days,  $p = 0.004$ ,  $d = 1.00$ ) and at 36  
113 months ( $t = 3.70$ , 95% CI 54.60 to 186.36 days,  $p = < 0.001$ ,  $d = 0.91$ ). Age in days was not  
114 included in the model as a fixed effect, as this had already been corrected for by using age-  
115 corrected T scores (MSEL and CBCL) and age-corrected standard scores (VABS). Post hoc

116 T-tests were carried out to further explore group differences on the MSEL and VABS at each  
117 timepoint.

118 Missing data were imputed using the maximum likelihood option. A p value of <0.05 was  
119 considered as significant. For post-hoc tests, a corrected p value of <0.01 was considered  
120 significant. Pearson Chi-squared tests were carried out for proportion of participants meeting  
121 autism threshold on the ADOS-2/BOSA/ADI-R (as outlined in the **Supplementary**  
122 **materials**). Mann-Whitney non-parametric analyses were used to compare ADI-R subscale  
123 means due to non-normality.

## 124 **RESULTS**

125 35 children with NF1 and 29 TD participants were recruited. **Table 1** provides further details  
126 of the demographic characteristics and number of participants per measure. 32 of the  
127 participants with NF1 had an inherited pathogenic variant, 2 arose de novo and 1 had an  
128 unknown mechanism of inheritance.

### 129 **Trajectories of cognitive and adaptive behavioural development**

130 **Table 2** summarises the results of the linear mixed models for each of the measures described  
131 below and post-hoc statistics are presented in **Supplementary Materials**.

132 On the MSEL, the developmental trajectory of children with NF1 differed significantly  
133 compared to the trajectory of TD children across all subscales (Visual Reception, Fine Motor,  
134 Receptive Language, Expressive Language, Early Learning Composite), with slower progress  
135 in the NF1 group. There was also a significant effect of Timepoint within the model;  
136 cognitive skills increased for all children as they aged, irrespective of group membership. The  
137 interaction between Group and Timepoint also reached statistical significance for all MSEL  
138 subscales (**Figure 1**). Pairwise comparisons showed significant differences between the NF

139 and TD groups on all MSEL domains at 5, 24 and 36 months. Only lower Fine Motor skills  
140 were observed at 10 months in the NF1 group, with no differences between the groups at 14  
141 months.

142 The trajectories of adaptive behavioural skills development were significantly different in  
143 NF1 when compared with TD children on four subscales of the VABS; Communication  
144 abilities, Daily living skills, Motor Skills and the Adaptive behaviour Composite domain,  
145 with slower progress in the NF1 group. However, there was no significant difference between  
146 children with NF1 and TD children on the Socialization domain. Adaptive behavioural skills  
147 increased significantly for all children over time irrespective of group membership. The  
148 interaction between Group and Timepoint also reached statistical significance for all VABS  
149 subscales (**Figure 2**). Pairwise comparisons showed that the NF1 participants scored  
150 significantly lower than TD participants in Daily living skills, Motor skills and the Adaptive  
151 Behavior Composite at 10 months, on all VABS domains at 24 months, but only on  
152 communication at 36 months.

### 153 **ADHD trait development**

154 Children with NF1 showed higher mean levels of ADHD traits on the CBCL DSM-ADHD  
155 subscale than TD children (**Figure 3 and Table 2**). 10.5% of NF1 participants at 36 months  
156 had a T-score over 65, suggesting clinically significant ADHD traits. There was no  
157 significant effect of Age or interaction between group and Age within this model, as the  
158 trajectory in children with NF1 paralleled the trajectory of TD children over time, suggesting  
159 similar patterns of change over time. There was no significant difference in CBCL score  
160 between male and female participants.

### 161 **Autism trait development**

162 Mean total ADOS-2 scores were higher in the NF1 group as compared to the TD group. 48%  
163 of NF1 participants at 24 months scored above threshold for autism on the ADOS-2 or BOSA-  
164 MV instruments, compared to 0% of TD children ( $X^2(1) = 15.51, p < 0.001$ ) (**Table 3**). More  
165 male than female participants reached instrumental threshold for autism in the NF1 group ( $X^2$   
166  $(1) = 6.24, p = 0.01$ ).

167 At 36 months, 31% of participants in the NF1 group scored above threshold for autism on the  
168 ADOS-2 or BOSA. This was not statistically significant ( $X^2(1) = 0.21, p = 0.65$ ), as 25% of TD  
169 participants also scored above threshold (although no TD participants gained an eventual  
170 research classification of autism) (**Table 3**). There were no statistically significant sex  
171 differences between the autism and non-autism participants in either the NF1 ( $X^2(1) = 2.52,$   
172  $p = 0.11$ ) or TD groups ( $X^2(1) = 1.11, p = 0.29$ ).

173 On the ADI-R at 36 months, there were significant differences, with higher mean scores on  
174 each of the 4 subscales in NF1 compared to TD participants ( $p < 0.001$ ) (**Figure 4 and Table**  
175 **3**).

176 When combining the ADI-R and ADOS-2/BOSA at 36 months to give a research classification  
177 of autism, as detailed in the **Supplementary materials**, 14% of the NF1 cohort met criteria for  
178 autism compared to 0% of TD participants; this was also statistically not significant ( $X^2(1) =$   
179  $2.71, p = 0.10$ ) (**Table 3**).

## 180 **DISCUSSION**

181 To our knowledge, this is the first study to systematically investigate the developmental  
182 trajectories of cognitive and behavioural development in children with NF1 from 5 to 36  
183 months of age using both objective and parental report measures. Our study suggests  
184 significantly lower trajectories of cognitive, motor, language and adaptive behaviour

185 development in the NF1 group, with an overall mean difference that strengthens over  
186 developmental time and is clear by 24 months of age.

187 On the MSEL, lower scores are first evident at 5 months, but these differences are  
188 strengthened by 24 months, and remain at 36 months. These results are consistent with a  
189 previous longitudinal study which showed significantly lower cognitive function in NF1 at 21  
190 months of age, which remained at the follow-up evaluation at 40 months.<sup>14</sup> It is interesting to  
191 note that only subtle group differences in cognitive functioning were observed at 10 and 14  
192 months. Our previous reports on the same cohort suggest differences arising in infancy in  
193 early auditory habituation and visual attention. Using an auditory habituation paradigm,  
194 Begum-Ali et al (2021) found developmental differences in auditory processing in infants  
195 with NF1 at 10 and 14 months, possibly suggestive of alterations in early sensory processing  
196 and specialisation.<sup>16</sup> Such early-stage processing differences that typically present in the first  
197 year of life may represent the beginning of a series of compensatory and adaptive brain  
198 processes that trigger an alternative trajectory of subsequent development.<sup>25,26</sup> Further, based  
199 on the results of the parent rated VABS, there may be differences in the pace of  
200 developmental change in the NF1 group with periods of ‘catch-up’ over time.

201 Our results indicate that levels of ADHD traits are higher in the NF1 group but were in the  
202 clinically significant range for only 10.5% at 36 months. Behavioural features of ADHD  
203 generally tend to peak in the school-age period, which has also been noted in NF1 with rates  
204 of ADHD as high as 50%.<sup>6</sup> Animal model studies suggest that dopaminergic dysfunction in  
205 NF1 underlies attentional deficits.<sup>27</sup> Clinically, the ADHD symptomatology seen in NF1 is  
206 very similar to idiopathic ADHD. However, in-depth analyses of neurophysiological  
207 processes underlying attention difficulties in NF1 suggests differences in cognitive control  
208 processes. Further understanding of these processes will be needed to move away from  
209 generic pharmacological intervention for ADHD and develop more personalised approaches.

210 Of note, only 3 participants at 36 months gained a T-score >65 however all of these  
211 participants also met research criteria for autism, in keeping with previous research indicating  
212 that autism and ADHD often co-occur in NF1 children.<sup>6</sup>

213 We hypothesised that higher proportions of the NF1 cohort would demonstrate autism traits  
214 on administered instruments at 24 and 36 months compared to TD participants. Almost half  
215 of the NF1 sample met instrumental threshold for autism at 24 months on the observer rated  
216 measures, but this was somewhat attenuated at 36 months (31%). When combining both the  
217 parental interview (ADI-R) and the observer rated measures (ADOS-2 or BOSA-MV), 14%  
218 of the NF1 sample met research classification for autism at 36 months. These results were  
219 statistically non-significant (most likely due to sample size), however they are consistent with  
220 previous studies which suggested rates of co-occurring autism in NF1 between 10-25%.<sup>7</sup>  
221 Given that the autism behavioural phenotype in NF1 is broadly similar to idiopathic autism,<sup>28</sup>  
222 it will be important to identify similarities and differences in early-stage markers in the two  
223 cohorts.

224 Consistent with a previous longitudinal study of NF1 children aged 21-40 months,<sup>13</sup> we  
225 largely found no sex differences in the trajectories of cognitive, behavioural or social  
226 development. These sex differences may emerge at a later timepoint, as there are significant  
227 sex differences observed in cross-sectional studies in school-age children with NF1. Males  
228 are more likely to demonstrate differences in learning and social functioning, mirroring the  
229 pattern seen in the general population.<sup>5,29</sup> Longitudinal studies of infants with high familial  
230 likelihood of neurodevelopmental conditions such as autism or ADHD have found that  
231 females in general perform better than males in all dimensions of cognitive functioning.<sup>30</sup>  
232 Alternatively, sex differences may not have been noted in our sample due to the relatively  
233 small sample size.

234 Methodological strengths of our study included tracking of a prospectively ascertained  
235 sample of children with NF1. Limitations include a relatively small sample size due to  
236 variable retention and rolling recruitment. The NF1 group was composed primarily of  
237 children with an inherited pathogenic variant, due to the early age at which assessments  
238 began. Our TD group showed a higher than expected proportion of participants reaching  
239 threshold for autism at 36 months on the ADOS-2/BOSA, however when combined with the  
240 ADI-R, none of the TD group was given a research classification of autism. Due to COVID  
241 limitations we utilised the BOSA for some participants, which is administered online and  
242 may not gather as accurate a picture of traits as ADOS-2. Finally, research thresholds using  
243 the ADI-R and ADOS/BOSA rather than gold-standard clinical best estimates were used for  
244 the autism classification in the NF1 cohort.

## 245 **CONCLUSION**

246 Our results collectively suggest that the NF1 brain development is atypical, with early-stage  
247 sensory processing difficulties seen in infancy consolidated to behavioural phenotypic  
248 differences by 24 months.<sup>15,16</sup> Clinically, this highlights that developmental monitoring and  
249 referral for early interventions should be considered by the age of 2 in children with NF1.  
250 Intervention targeting neurocognitive modifiers such as executive attention or social  
251 engagement may ameliorate the impact of genetic or environmental vulnerabilities on the  
252 developing brain.<sup>29</sup> Future work should include replication of our findings in larger cohorts,  
253 investigating the similarities and differences in the developmental profiles seen in NF1 to  
254 other cohorts of infants at higher likelihood of common neurodevelopmental conditions such  
255 as autism and ADHD. This will inform potential intervention development.

## 256 **Acknowledgments**

257 We are extremely grateful to the families who have given their time for our research, and NF

258 charities particularly Nerve Tumours UK and Childhood Tumour Trust. We would like to  
259 thank the researchers who assisted with recruitment and data collection; Kim Davies, Janice  
260 Fernandes, Marian Greensmith, Natalie Vaz, Claire Bennett, Olivia Mitchell, Imogen Crook,  
261 Amelia Pearson, Henna Ahmed and Sofia Ahmed. We are grateful to the placement students  
262 who assisted with data collection; Francesca Conti, Zoë Freeman and Meg Jackson.

### 263 **Members of the EDEN-STAARS team**

264 The STAARS team includes: Mary Agyapong, Tessel Bazelmans, Leila Dafner, Mutluhan  
265 Ersoy, Teodora Gliga, Amy Goodwin, Rianne Haartsen, Hanna Halkola, Alexandra Hendry,  
266 Rebecca Holman, Sarah Kalwarowsky, Sarah Lloyd-Fox, Luke Mason, Nisha Narvekar, Laura  
267 Pirazzoli and Chloë Taylor.

268 The EDEN team includes: Grace Vassallo, Judith Eelloo, D. Gareth Evans, Siobhan West,  
269 Eileen Hupton, Louise Robinson, Neeta Lakhani, Brian Wilson, Deborah Osio, Charles Shaw-  
270 Smith, Natalie Canham and Saba Sharif.

## REFERENCES

- 271 1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. (2010). Birth  
272 incidence and prevalence of tumor-prone syndromes: estimates from a UK family  
273 genetic register service. *Am J Med Genet A*.152A(2):327-332. 10.1002/ajmg.a.33139  
274 2. Klein-Tasman BP, Janke KM, Luo W, Casnar CL, Hunter SJ, Tonsgard J, et al.  
275 (2014). Cognitive and psychosocial phenotype of young children with  
276 neurofibromatosis-1. *J Int Neuropsychol Soc*.20(1):88-98.  
277 10.1017/S1355617713001227  
278 3. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. (2021).  
279 Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an  
280 international consensus recommendation. *Genet Med*.23(8):1506-1513.  
281 10.1038/s41436-021-01170-5  
282 4. Brei NG, Klein-Tasman BP, Schwarz GN, Casnar CL. (2014). Language in young  
283 children with neurofibromatosis-1: relations to functional communication, attention,  
284 and social functioning. *Res Dev Disabil*.35(10):2495-2504.  
285 10.1016/j.ridd.2014.06.016




- 286 5. Hyman SL, Shores A, North KN. (2005). The nature and frequency of cognitive  
287 deficits in children with neurofibromatosis type 1. *Neurology*.65(7):1037-1044.  
288 10.1212/01.wnl.0000179303.72345.ce
- 289 6. Garg S, Lehtonen A, Huson SM, Emsley R, Trump D, Evans DG, et al. (2013).  
290 Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from  
291 a population-based study. *Dev Med Child Neurol*.55(2):139-145.  
292 10.1111/dmcn.12043
- 293 7. Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM. (2018).  
294 Social Function and Autism Spectrum Disorder in Children and Adults with  
295 Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis. *Neuropsychol*  
296 *Rev*.28(3):317-340. 10.1007/s11065-018-9380-x
- 297 8. Beaussart-Corbat ML, Barbarot S, Farges D, Martin L, Roy A. (2021). Executive  
298 functions in preschool-aged children with neurofibromatosis type 1: Value for early  
299 assessment. *J Clin Exp Neuropsychol*.43(2):163-175.  
300 10.1080/13803395.2021.1893277
- 301 9. Casnar CL, Klein-Tasman BP. (2017). Parent and Teacher Perspectives on Emerging  
302 Executive Functioning in Preschoolers With Neurofibromatosis Type 1: Comparison  
303 to Unaffected Children and Lab-Based Measures. *J Pediatr Psychol*.42(2):198-207.  
304 10.1093/jpepsy/jsw042
- 305 10. Lorenzo J, Barton B, Acosta MT, North K. (2011). Mental, motor, and language  
306 development of toddlers with neurofibromatosis type 1. *J Pediatr*.158(4):660-665.  
307 10.1016/j.jpeds.2010.10.001
- 308 11. Lorenzo J, Barton B, Arnold SS, North KN. (2013). Cognitive features that  
309 distinguish preschool-age children with neurofibromatosis type 1 from their peers: a  
310 matched case-control study. *J Pediatr*.163(5):1479-1483 e1471.  
311 10.1016/j.jpeds.2013.06.038
- 312 12. Soucy EA, Gao F, Gutmann DH, Dunn CM. (2012). Developmental delays in  
313 children with neurofibromatosis type 1. *J Child Neurol*.27(5):641-644.  
314 10.1177/0883073811423974
- 315 13. Garg S, Wan MW, Begum-Ali J, Kolesnik-Taylor A, Green J, Johnson MH, et al.  
316 (2022). Early Developmental Trajectories in Infants With Neurofibromatosis 1. *Front*  
317 *Psychol*.13:795951. 10.3389/fpsyg.2022.795951
- 318 14. Lorenzo J, Barton B, Arnold SS, North KN. (2015). Developmental trajectories of  
319 young children with neurofibromatosis type 1: a longitudinal study from 21 to 40  
320 months of age. *J Pediatr*.166(4):1006-1012 e1001. 10.1016/j.jpeds.2014.12.012
- 321 15. Wessel LE, Gao F, Gutmann DH, Dunn CM. (2013). Longitudinal analysis of  
322 developmental delays in children with neurofibromatosis type 1. *J Child*  
323 *Neurol*.28(12):1689-1693. 10.1177/0883073812462885
- 324 16. Begum-Ali J, Kolesnik-Taylor A, Quiroz I, Mason L, Garg S, Green J, et al. (2021).  
325 Early differences in auditory processing relate to Autism Spectrum Disorder traits in  
326 infants with Neurofibromatosis Type I. *J Neurodev Disord*.13(1):22. 10.1186/s11689-  
327 021-09364-3
- 328 17. Carter Leno V, Begum-Ali J, Goodwin A, Mason L, Pasco G, Pickles A, et al. (2022).  
329 Infant excitation/inhibition balance interacts with executive attention to predict  
330 autistic traits in childhood. *Mol Autism*.13(1):46. 10.1186/s13229-022-00526-1
- 331 18. Mullen EM. *Mullen scales of early learning (AGS ed.)*. Circle Pines, MN: American  
332 Guidance Service Inc.; 1995.
- 333 19. Sparrow SS. Vineland Adaptive Behavior Scales. In: Kreutzer JS, DeLuca J, Caplan  
334 B, editors. *Encyclopedia of Clinical Neuropsychology*. New York, NY: Springer New  
335 York; 2011. p. 2618-2621.


- 336 20. Achenbach TMaR, L.A. *Manual for the ASEBA School-Age Forms and Profiles*.  
337 Burlington, VT: University of Vermont Research Center for Children, Youth, &  
338 Families; 2001.
- 339 21. Lord C, Risi S, Lambrecht L, Cook EH, Jr., Leventhal BL, DiLavore PC, et al.  
340 (2000). The autism diagnostic observation schedule-generic: a standard measure of  
341 social and communication deficits associated with the spectrum of autism. *J Autism*  
342 *Dev Disord.*30(3):205-223.
- 343 22. Luyster R, Gotham K, Guthrie W, Coffing M, Petrak R, Pierce K, et al. (2009). The  
344 Autism Diagnostic Observation Schedule-toddler module: a new module of a  
345 standardized diagnostic measure for autism spectrum disorders. *J Autism Dev*  
346 *Disord.*39(9):1305-1320. 10.1007/s10803-009-0746-z
- 347 23. Dow D, Holbrook A, Toolan C, McDonald N, Sterrett K, Rosen N, et al. (2022). The  
348 Brief Observation of Symptoms of Autism (BOSA): Development of a New Adapted  
349 Assessment Measure for Remote Telehealth Administration Through COVID-19 and  
350 Beyond. *J Autism Dev Disord.*52(12):5383-5394. 10.1007/s10803-021-05395-w
- 351 24. Lord C, Rutter M, Le Couteur A. (1994). Autism Diagnostic Interview-Revised: a  
352 revised version of a diagnostic interview for caregivers of individuals with possible  
353 pervasive developmental disorders. *J Autism Dev Disord.*24(5):659-685.  
354 10.1007/BF02172145
- 355 25. Johnson MH, Jones EJ, Gliga T. (2015). Brain adaptation and alternative  
356 developmental trajectories. *Dev Psychopathol.*27(2):425-442.  
357 10.1017/S0954579415000073
- 358 26. Johnson MH, Charman T, Pickles A, Jones EJM. (2021). Annual Research Review:  
359 Anterior Modifiers in the Emergence of Neurodevelopmental Disorders (AMEND)-a  
360 systems neuroscience approach to common developmental disorders. *J Child Psychol*  
361 *Psychiatry.*62(5):610-630. 10.1111/jcpp.13372
- 362 27. Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH.  
363 (2013). Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.  
364 *Ann Neurol.*73(2):309-315. 10.1002/ana.23793
- 365 28. Chisholm AK, Haebich KM, Pride NA, Walsh KS, Lami F, Ure A, et al. (2022).  
366 Delineating the autistic phenotype in children with neurofibromatosis type 1. *Mol*  
367 *Autism.*13(1):3. 10.1186/s13229-021-00481-3
- 368 29. Garg S, Heuvelman H, Huson S, Tobin H, Green J, Northern UKNFRN. (2016). Sex  
369 bias in autism spectrum disorder in neurofibromatosis type 1. *J Neurodev*  
370 *Disord.*8:26. 10.1186/s11689-016-9159-4
- 371 30. Messinger DS, Young GS, Webb SJ, Ozonoff S, Bryson SE, Carter A, et al. (2015).  
372 Early sex differences are not autism-specific: A Baby Siblings Research Consortium  
373 (BSRC) study. *Mol Autism.*6:32. 10.1186/s13229-015-0027-y
- 374 31. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, et al. (2006).  
375 Combining information from multiple sources in the diagnosis of autism spectrum  
376 disorders. *J Am Acad Child Adolesc Psychiatry.*45(9):1094-1103.  
377 10.1097/01.chi.0000227880.42780.0e

## TABLES AND FIGURES


**Figure 1:** Estimated marginal mean scores of NF1 and TD groups on the Mullen Scale of Early Learning at 5, 10, 14, 24 and 36 months. Error bars represent 95% confidence intervals.



**Figure 2:** Estimated marginal mean scores of NF1 and TD groups on the Vineland Adaptive Behaviour Scale at 5, 10, 14, 24 and 36 months. Error bars represent 95% confidence intervals.




**Figure 3:** Estimated marginal mean scores of NF1 and TD groups on the CBCL- DSM ADHD Subscale (T scores used) at 24 and 36 months. Error bars represent 95% confidence intervals.



**Figure 4:** Mean values and Mann-Whitney results for subscales A-D on the Autism Diagnostic Interview-Revised (ADI-R). A – qualitative abnormalities in reciprocal social interaction, B – qualitative abnormalities in communication, C – restricted, repetitive and stereotyped patterns of behaviour and D – abnormalities of development evident at or before 36 months.

#### ADI-R



	<b>Mann-Whitney scores</b>
A:Reciprocal Social Interaction	Mean rank 14.14 vs 30.72, U=83.50, z=-4.03, p=<0.001*
B:Communication	Mean rank 14.39 vs 30.57, U=88.00, z=-3.95, p=<0.001*
C:Restrictive, Repetitive, Stereotyped Behaviour	Mean rank 16.50 vs 29.30, U=126.00, z=-3.23, p=0.001*
D:Abnormalities evident at or before 36 months	Mean rank 12.81 vs 31.52, U=59.50, z=-4.79, p=<0.001*

**Table 1:** Demographic characteristics and number of participants at each Timepoint

	5 Months				10 Months				14 Months				24 months				36 months			
	TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group	
	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]	<i>n</i>	<i>Mean</i> [ <i>SD</i> ]
Age at time of testing in days	26	179.19 [14.05]	15	194.73 [17.85]	27	321.93 [16.70]	23	327 [17.11]	23	447.7 [18.37]	27	449.74 [23.41]	24	762.25 [36.07]	29	795.41 [90.98]	20	1135.45 [55.31]	30	1255.93 [164.87]
Sex (n) M/F	26	17/9	15	8/7	27	16/11	23	12/11	23	13/10	27	13/14	24	13/11	29	14/15	20	12/8	30	14/16
Maternal education (n) (Secondary/undergrad/ postgrad)	23	2/8/13	12	8/2/2	26	2/10/14	23	15/5/3	23	2/7/14	25	14/8/3	23	2/8/13	26	15/8/3	19	1/7/11	26	16/7/3

**Table 2:** Linear mixed modelling F statistic and p values of fixed effects for all the outcome measures. Maternal education was included in all models as a covariate. *df*= degrees of freedom, *F* statistic, *p* value, \*= significant results

	MSEL Visual Reception			MSEL Fine Motor			MSEL Receptive Language			MSEL Expressive Language			MSEL Early Learning Composite		
	<i>df</i>	<i>F</i>	<i>P</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>
<b>Intercept</b>	1, 56	3567.94	<.001*	1,53	1786.79	<.001*	1, 53	3036.60	<.001*	1, 56	2590.40	<.001*	1, 53	4364.92	<.001*
<b>Group</b>	1, 56	84.72	<.001*	1,53	64.16	<.001*	1, 53	111.37	<.001*	1, 57	36.59	<.001*	1, 53	85.30	<.001*
<b>Timepoint</b>	4, 178	38.46	<.001*	4, 174	7.11	<.001*	4, 177	53.75	<.001*	4, 179	19.57	<.001*	4, 170	61.97	<.001*
<b>Sex</b>	1, 54	0.18	.676	1, 51	0.17	.679	1, 50	0.38	.541	1, 54	1.33	.254	1, 51	0.20	.657
<b>Group x Timepoint</b>	4, 178	30.83	<.001*	4, 174	13.65	<.001*	4, 177	23.51	<.001*	4, 179	20.03	<.001*	4, 170	41.30	<.001*
	VABS Communication			VABS Daily Living Skills			VABS Socialization			VABS Motor Skills			Vineland Adaptive Behaviour Composite		
	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>	<i>df</i>	<i>F</i>	<i>p</i>
<b>Intercept</b>	1, 50	7107.57	<.001*	1, 55	8034.63	<.001*	1, 59	7396.78	<.001*	1, 54	5814.12	<.001*	1, 57	6986.46	<.001*
<b>Group</b>	1, 50	14.15	<.001*	1, 55	5.60	.022*	1, 59	2.02	.160	1, 54	22.55	<.001*	1, 57	13.92	<.001*
<b>Timepoint</b>	4, 148	10.97	<.001*	4, 156	9.57	<.001*	4, 150	3.72	.006*	4, 149	12.24	<.001*	4, 143	8.24	<.001*
<b>Sex</b>	1, 48	1.39	.245	1, 53	1.84	.180	1, 58	2.34	.132	1, 53	.52	.475	1, 56	2.29	.136
<b>Group x Timepoint</b>	4, 148	6.78	<.001*	4, 156	3.95	.004*	4, 150	5.31	<.001*	4, 149	2.65	.035*	4, 143	8.22	<.001*
CBCL DSM-ADHD Subscale															
	<i>df</i>	<i>F</i>	<i>p</i>												
<b>Intercept</b>	1,50	6252.67	<.001*												
<b>Group</b>	1, 50	11.21	.002*												
<b>Timepoint</b>	1, 46	0.02	.885												
<b>Sex</b>	1, 50	1.97	.167												
<b>Group x Timepoint</b>	1, 46	0.85	.361												



**Table 3:** Descriptive statistics including means and SDs for the NF1 and TD group at 24 and 36 month time points for ADI-R, ADOS, BOSA and CBCL

	24 months				36 months			
	TD group		NF1 Group		TD group		NF1 Group	
	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>
<b>Autism Diagnostic Interview - Revised (ADI-R) Diagnostic Algorithm</b>								
Qualitative Abnormalities in Reciprocal Social Interaction (A)					18	0.94(1.00)	30	5.23(4.79)
Qualitative Abnormalities in Communication (B)					18	0.67 (0.97)	30	5.03(4.42)
Restricted, Repetitive and Stereotyped Patterns of Behaviour (C)		N/A		N/A	18	0.39 (0.61)	30	2.13(2.60)
Abnormality of Development Evident at or Before 36 Months (D)					18	0.06 (0.24)	30	1.83(1.34)
Meeting threshold for autism on ADI-R					18	0 (0%)	30	5 (17%)
Not meeting threshold for autism on ADI-R					18	18 (100%)	30	25 (83%)
<b>Autism Diagnostic Observation Schedule-2 (ADOS-2)</b>								
Module (n) (Toddler/Module 1/Module 2)	24	24,0,0	24	21,3,0	20	0,0,20	17	0,16,1
Total scores	24	3.67(1.95)	24	8.08(6.64)	20	4.35(3.42)	17	4.47(3.86)
Social Affect scores	24	3.13(1.80)	24	6.83(5.75)	20	3.60(2.84)	17	3.65(3.02)

Restrictive and Repetitive Behaviour scores	24	0.54(0.72)	24	1.25(1.29)	20	0.80(0.95)	17	0.82(1.24)
Number reaching threshold for Autism Spectrum Disorder or Autism on ADOS-2	24	0 (0%)	24	11 (46%)	20	5 (25%)	17	4 (24%)
<b>Brief Observation of Symptoms of Autism (BOSA-MV)</b>								
Module (n) (Toddler/Module 1)			3	2,1			12	0,12
Total scores	0	0,0	3	12.33(4.93)	0	0,0	12	8.17(2.66)
Algorithm scores			3	6.00(2.00)			12	4.42(1.44)
Number reaching threshold for Autism Spectrum Disorder on the BOSA			3	2 (67%)			12	5 (42%)
<b>ADOS/BOSA combined</b>								
Number of participants reaching threshold for Autism	24	0 (0%)	27	13 (48%)	20	5 (25%)	29	9 (31%)
Number of participants not reaching threshold for Autism	24	24 (100%)	27	14 (52%)	20	15 (75%)	29	20 (69%)
<b>Number of participants reaching threshold for Autism on both ADI-R and ADOS/BOSA</b>								
		N/A		N/A	18	0 (0%)	29	4 (14%)
<b>Child Behaviour Checklist ADHD subscale</b>								
T score	22	51.86(2.49)	27	55.56(7.84)	21	51.10(1.45)	28	57.14(6.88)

## **Supplementary materials**

### **Procedure**

The study assessments took place at the Division of Psychology and Mental Health, University of Manchester, and the Centre for Brain and Cognitive Development, Birkbeck, University of London. Prior written informed consent was obtained from the parent. Testing took place if the child was physically well and content. Participant families were provided with reimbursement for expenses. The behavioural measures described below were part of a more comprehensive experimental protocol.

### **Measures**

*ADOS-2*: Based on the expressive language ability of the participants, either the Toddler module, Module 1 or Module 2 of the ADOS-2 were used at 24 and 36 months (**Table 2**). Coding was carried out from videos, with an inter-rater reliability of 79.1% for the NF1 cohort.

*BOSA-MV*: Based on the expressive language ability of the participants, either the Toddler module or Module 1 of the BOSA-MV were used at 24 and 36 months (**Table 2**).

*ADI-R*: Four subscales are produced: A – qualitative abnormalities in reciprocal social interaction, B – qualitative abnormalities in communication, C – restricted, repetitive and stereotyped patterns of behaviour and D – abnormalities of development evident at or before 36 months. Each subscale has an algorithm score cut-off for Autism.

## **Classification of autism**

In our paper, the following thresholds are used on the ADOS-2 and BOSA-MV to indicate autism traits at 24 months:

- 'mild-to-moderate' or 'moderate-to-severe' concern on the ADOS-2 Toddler module
- 'autism-spectrum' or 'autism' on ADOS-2 Module 1
- a score of 6 on the BOSA-MV toddler module or a score of 5 on the BOSA-MV Module 1.

Luyster et al (2009) state that at least 95% of children with Autism Spectrum Disorder and no more than 10% of typically developing children would fall into the two groups suggesting clinical concern on the ADOS Toddler module (mild-to-moderate and moderate-to-severe).<sup>22</sup> Dow et al (2022) recommend a cut-off of 6 for Autism Spectrum Disorder for the BOSA-MV toddler module and a score of 5 as a cut-off for the BOSA-MV Module 1.<sup>23</sup>

Participants were assigned a research instrumental classification of autism at 36 months if they scored either:


- 'autism-spectrum' or 'autism' on ADOS-2 Module 1 or 2
- a cut off of 5 on the BOSA-MV Module 1

AND

- Met threshold for subscale A and came within one point of B, or met B and came within one point of A on the ADI-R, as suggested by Risi et al (2006).<sup>31</sup>

### Study numbers

Flowchart showing the number of NF1 and TD participants at each time point in the study. Flexible recruitment and variable retention across visits meant that the sample size varied between time points.



**Descriptive statistics including means and SDs for the NF1 and TD group at the five assessment time points for Mullen Scales of Early Learning and Vineland Adaptive Behaviour Scale**

	5 Months				10 Months				14 Months				24 months				36 months			
	TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group		TD group		NF1 Group	
	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>	<i>n</i>	<i>Mean</i> <i>[SD]</i>
<b>Mullen Scale of Early Learning T scores</b>																				
Gross Motor	26	43.69 [9.41]	15	37.40 [9.72]	27	34.89 [11.78]	23	30.00 [10.25]	23	36.74 [13.38]	27	31.96 [12.75]	-	-	26	35.04 [8.45]	-	-	-	-
Visual reception	26	47.27 [6.33]	15	37.47 [11.53]	27	48.85 [7.99]	23	43.96 [8.08]	23	35.09 [8.88]	27	33.67 [5.17]	24	59.63 [10.66]	27	33.11 [9.83]	19	67.58 [9.34]	27	40.63 [8.65]
Fine motor	26	42.92 [10.46]	15	32.8 [6.99]	27	51.63 [12.88]	23	42.13 [11.29]	23	49.65 [12.18]	27	43.85 [11.07]	24	56.00 [12.98]	27	33.89 [10.49]	19	64.68 [11.32]	27	31.22 [9.67]
Receptive language	26	36.88 [11.28]	14	25.71 [9.31]	27	39.26 [8.96]	23	34.87 [7.73]	23	32.87 [6.50]	27	28.33 [6.01]	24	57.67 [8.73]	27	33.85 [10.65]	19	65.84 [6.30]	27	35.89 [9.70]
Expressive language	26	41.85 [7.45]	15	35.13 [6.35]	27	36.85 [9.89]	23	39.35 [12.56]	23	37.09 [8.81]	27	38.19 [10.18]	24	55.42 [12.30]	27	34.52 [8.70]	19	60.84 [8.51]	26	39.50 [10.57]
Early Learning Composite Scores	26	85.00[9.32]	14	67.86 [9.46]	27	88.89 [12.19]	23	81.13 [10.70]	23	78.78 [11.99]	27	73.67 [7.30]	24	114.25[17.91]	27	81.48[17.91]	19	129.05[11.75]	26	75.88[13.45]

<b>Vineland Adaptive Behaviour Scale Standard Scores</b>																				
Communication																				
Daily living skills	22	94.95 [10.91]	14	95.71 [14.04]	21	92.86 [12.76]	23	86.13 [14.91]	19	96.11 [10.49]	24	91.04 [10.08]	22	112.14 [8.82]	22	93.41 [7.5]	12	105.08 [8.58]	30	90.73 [14.23]
Socialisation	22	86.32 [19.86]	14	92.71 [18.26]	22	102.45 [10.76]	23	93.74 [9.14]	18	93.44 [8.39]	23	95.52 [10.85]	22	108.36 [7.36]	22	96.14 [9.25]	12	104 [10.06]	30	97.9 [14.67]
Motor	23	98.70 [12.26]	14	101.36 [14.21]	22	98.77 [10.04]	21	92.76 [14.59]	18	94.22 [9.79]	23	97.96 [9.43]	22	104.64 [7.86]	22	94.55 [7.71]	12	103.25 [6.05]	30	98.47 [15.78]
Adaptive behaviour composite	21	88.67 [12.99]	14	85.07 [13.37]	21	95.76 [16.86]	23	79.91 [14.86]	18	101.67 [9.49]	24	93.42 [11.14]	22	102.41 [7.93]	22	93.05 [8.67]	12	92 [8.52]	30	83.77 [13.13]
	19	90.63 [11.93]	14	92.29 [11.13]	20	96.80 [10.44]	21	85.86 [12.85]	17	95.29 [9.73]	23	93.17 [9.36]	22	108.05 [8.16]	22	92.73 [5.78]	12	100.92 [8.58]	30	91.4 [14.62]

\*Missing data not included in n, mean or SD but kept in model for imputation

**Post-hoc T-test analysis for the NF1 and TD group means at the five assessment time points for Mullen Scales of Early Learning and Vineland Adaptive Behaviour Scale. Bonferroni corrected alpha value = <0.01**

	<b>5 Months T-test (NF1 group – TD group)</b>	<b>10 Months T-test (NF1 group – TD group)</b>	<b>14 Months T-test (NF1 group – TD group)</b>	<b>24 Months T-test (NF1 group – TD group)</b>	<b>36 Months T-test (NF1 group – TD group)</b>
<b>Mullen Scale of Early Learning T Scores</b>					
Visual Reception	t(39)=-3.53, p<0.001*	t(48)=-2.15, p=0.037	t(48)=-0.70, p=0.485	t(49)=-9.24, p<0.001*	t(44)=-10.07, p <0.001*
Fine Motor	t(39)=-3.34, p=0.002*	t(48)=-2.75, p=0.008*	t(48)=-1.76, p=0.084	t(49)=-6.72, p <0.001*	t(44)=-10.77, p <0.001*
Receptive Language	t(38)=-3.17, p=0.003*	t(48)=-1.84, p=0.072	t(48)=-2.56, p=0.014	t(49)=-8.67, p <0.001*	t(44)=-11.80, p <0.001*
Expressive Language	t(39)=-2.93, p=0.006*	t(48)= 0.79, p=0.436	t(48)=0.40, p=0.688	t(49)=-7.06, p <0.001*	t(44)=-7.24, p <0.001*
Early Learning Composite Scores	t(38)=-5.52, p<0.001*	t(48)=-2.37, p=0.022	t(48)=-1.85, p=0.07	t(49)=-6.41, p <0.001*	t(44)=-13.80, p <0.001*
<b>Vineland Adaptive Behaviour Scale Standard Scores</b>					
Communication	t(34)=0.182, p=0.857	t(42)=-1.601, p=0.117	t(41)=0.79, p=0.116	t(42)=-7.59, p <0.001*	t(40)=-3.25, p <0.001*
Daily Living Skills	t(34)=0.971, p=0.338	t(43)=-2.933, p=0.005*	t(39)=0.67, p=0.507	t(42)=-4.85, p <0.001*	t(40)=-1.32, p 0.195
Socialization	t(35)=0.603, p=0.550	t(41)=-1.580, p=0.122	t(39)=1.237, p=0.223	t(42)=-4.30, p <0.001*	t(40)=-1.02, p 0.316
Motor Skills	t(33)=-0.793, p=0.433	t(42)=0.585, p<0.001*	t(40)=-2.527, p=0.16	t(42)=-3.74, p <0.001*	t(40)=-2.00, p 0.052
Adaptive Behaviour Composite	t(31)=0.405, p=0.688	t(39)=-2.983, p<0.005*	t(38)=-0.696, p=0.490	t(42)=-7.19, p <0.001*	t(40)=-2.11, p 0.042



### MSEL post hoc tests

**NF1 vs TD at 5 months:** Visual Reception [t(39)=-3.53, p<0.001, CI (-15.42 to -4.18)], Fine Motor [t(39)=-3.34, p=0.002, CI (-16.26 to -3.98)], Receptive Language [t(38)=-3.17, p=0.003, CI (-18.31 to -4.03)], Expressive Language [t(39)=-2.93, p=0.006, CI (-11.35 to -2.07)], Early Learning Composite [t(38)=-5.52, p<0.001, CI (-23.43 to -10.86)]. **NF1 vs TD at 10 months:** Visual Reception [t(48)=-2.15, p=0.037, CI (-9.48 to -0.31)], Fine Motor [t(48)=-2.75, p=0.008, CI (-16.45 to -2.55)], Receptive Language [t(48)=-1.84, p=0.072, CI (-9.19 to 0.41)], Expressive Language [t(48)= 0.79, p=0.436, CI (-3.89 to 8.88)], Early Learning Composite [t(48)=-2.37, p=0.022, CI (-14.34 to -1.18)]. **NF1 vs TD at 14 months:** Visual Reception [t(48)=-0.70, p=0.485, CI (-5.48 to 2.64)], Fine Motor [t(48)=-1.76, p=0.084, CI (-12.41 to 0.81)], (Receptive Language [t(48)=-2.56, p=0.014, CI (-8.09 to -0.98)], Expressive Language [t(48)=0.40, p=0.688, CI (-4.36 to 6.56)], Early Learning Composite [t(48)=-1.85, p=0.07, CI (-10.67 to 0.44)]. **NF1 vs TD at 24 months:** Visual Reception [t (49)=-9.24, p<0.001, CI (-32.28 to -20.75)], Fine Motor [t(49)=-6.72, p<0.001, CI (-28.72 to -15.50)], Receptive Language [t(49)=-8.67, p<0.001, CI (-29.34 to -18.29)], Expressive Language [t(49)=-7.06, p<0.001, CI (-26.84 to -14.95)], Early Learning Composite [t(49)=-6.41, p<0.001, CI (-43.04 to -22.50)]. **NF1 vs TD at 36 months:** Visual Reception [t(44) =-10.07, p<0.001, CI (-32.35 to -21.55)], Fine Motor [t(44)=-10.77, p<0.001, CI (-39.73 to -27.20)], Receptive Language [t(44)=-11.80, p<0.001, CI (-35.07 to -24.84)], Expressive Language [t(44)=-7.24, p<0.001, CI (-27.29 to -15.40)], Early Learning Composite [t(44)=-13.80, p<0.001, CI (-60.94 to -45.40)].

### VABS post hoc tests

**NF1 vs TD at 5 months:** Communication [t(34)=0.182, p=0.857, CI (-7.72 to 9.24)], Daily

living skills [t(34)=0.971, p=0.338, CI (-6.99 to 19.78)], Socialization [t(35)=0.603, p=0.550, CI (-6.30 to 11.62)], Motor Skills [t(33)=-0.793, p=0.433, CI (-12.82 to 5.63)] and Adaptive behaviour Composite [t(31)=0.405, p=0.688, CI (-6.68 to 9.99)]. **NF1 vs TD at 10 months:** Communication [t(34)=0.182, p=0.857, CI (-15.2 to 1.80)], Daily living skills [t(43)=-2.933, p=0.005, CI (-14.7 to -2.72)], Socialization [t(35)=0.603, p=0.550, CI (-13.69 to 1.67)], Motor Skills [t(42)=0.585, p<0.001, CI (-28.5 to -9.2)] and Adaptive behaviour Composite [t(39)=-2.983, p<0.005, CI (-18.36 to -3.52)]. **NF1 vs TD at 14 months:** Communication [t(41)=0.79, p=0.116, CI (-11.43 to 1.3)], Daily living skills [t(39)=0.67, p=0.507, CI (-4.20 to 8.35)], Socialization [t(39)=1.237, p=0.223, CI (-2.37 to 9.84)], Motor Skills [t(40)=-2.527, p=0.16, CI (-14.85 to -1.65)] and Adaptive behaviour Composite [t(38)=-0.696, p=0.490, CI (-8.28 to 4.04)]. **NF1 vs TD at 24 months:** Communication [t(42)=-7.59, p <0.001, CI (-23.71 to -13.75)], Daily living skills [t(42)=-4.85, p <0.001, CI (-17.31 to -7.14)], Socialization [t(42)=-4.30, p <0.001, CI (-14.83 to -5.36)], Motor Skills [t(42)=-3.74, p <0.001, CI (-14.42 to -4.31)] and Adaptive behaviour Composite [t(42)=-7.19, p <0.001, CI (-19.62 to -11.02)]. **NF1 vs TD at 36 months:** Communication [t(40)=-3.25, p <0.001, CI (-23.27 to -5.43)], Daily living skills [t(40)=-1.32, p 0.195, CI (-15.46 to 3.26)], Socialization [t(40)=-1.02, p 0.316, CI (-14.31 to 4.75)], Motor Skills [t(40)=-2.00, p 0.052, CI (-16.54 to 0.08)] and Adaptive behaviour Composite [t(40)=-2.11, p 0.042, CI (-18.65 to -0.38)].